Heparin-appended polycaprolactone core/corona nanoparticles for site specific delivery of 5-fluorouracil

References

• Alanazi F, Haq N, Radwan AA, Alsarra IA, Shakeel F. 2015. Formulation and evaluation of cholesterol-rich nanoemulsion (LDE) for drug delivery potential of cholesteryl-maleoyl-5-fluorouracil. Pharm Dev Technol. 20:266–270.
   PubMed Web of Science ®Google Scholar
• Alanazi FK, Haq N, Radwan AA, Alsarra IA, Shakeel F. 2014. Cholesterol-rich nanoemulsions (LDE) for drug targeting of cholesteryl-succinyl-5-fluorouracil conjugate. Curr Nanosci. 10:287–229.
   Web of Science ®Google Scholar
• Alanazi FK, Haq N, Radwan AA, Alsarra IA, Shakeel F. 2014. Potential of lipid nanoemulsions for drug delivery of cholesteryl-hexahydrophthaloyl-5-fluorouracil. J Drug Deliv Sci Technol. 24:459–463.
   Web of Science ®Google Scholar
• Allen TM. 2002. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2:705–763.
   PubMed Web of Science ®Google Scholar
• Alsarra IA, Alarifi MN. 2004. Validated liquid chromatographic determination of 5-fluorouracil in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 804:435–439.
   PubMed Web of Science ®Google Scholar
• Ansifield FJ, Schroeder JM, Curreri AR. 1962. Five years clinical experience with 5-fluorouracil. JAMA. 181:295–299.
   PubMed Web of Science ®Google Scholar
• Ashley CE, Carnes EC, Phillips GK, Padilla D, Durfee PN, Brown PA, et al. 2011. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater. 10:389–397.
   PubMed Web of Science ®Google Scholar
• Boyle P, Levin B. 2008. World Cancer Report. World Health Organization Press.
   Google Scholar
• de Mattos AC, Khalil NM, Mainardes RM. 2013. Development and validation of an HPLC method for the determination of fluorouracil in polymeric nanoparticles. Braz J Pharma Sci. 49:117–126.
   Web of Science ®Google Scholar
• Demoré B, Benoit E, Maincent P, Hoffman M, Bessière J. 1998. Determination of heparin in aqueous solutions. J Clin Pharm Ther. 23:381–384.
   PubMed Web of Science ®Google Scholar
• Diasio RB, Harris BE. 1989. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 16:215–237.
   PubMed Web of Science ®Google Scholar
• Dieckmann Y, Collfen H, Hofmann H, Fink AP. 2009. Particle size distribution measurements of manganese-doped ZnS nanoparticles. Anal Chem. 81:3889–3895.
   PubMed Web of Science ®Google Scholar
• Garg A, Rai G, Lodhi S, Jain AP, Yadav AK. 2014. In-vitro and in-vivo assessment of dextran-appended cellulose acetate phthalate nanoparticles for transdermal delivery of 5-fluorouracil. Drug Deliv. 24:1–11.
   Web of Science ®Google Scholar
• Ghoshal K, Jacob ST. 1997. An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem Pharmacol. 53:1569–1575.
   PubMed Web of Science ®Google Scholar
• Hirsh J. 1991. Heparin. N Engl J Med. 324:1565–1574.
   PubMed Web of Science ®Google Scholar
• Hu Z, Xia X, Tang L. 2004. Process for synthesizing oil and surfactant-free hyaluronic acid nanoparticles and microparticles. US Patent App. 20,060/040,892.
   Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. 2010. Cancer statistics, 2010. CA Cancer J Clin. 60:277–300.
   PubMed Web of Science ®Google Scholar
• Kolhe P, Misra E, Kannan RM, Kanna S, Lieh-Lai M. 2003. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J Pharm. 259:143–160.
   PubMed Web of Science ®Google Scholar
• Martins AF, Pereira AGB, Fajardo AR, Rubira AF, Muniz EC. 2011. Characterization of polyelectrolytes complexes based on N, N, and N-trimethyl chitosan/heparin prepared at different pH conditions. Carbohydr Polym. 86:1266–1272.
   Web of Science ®Google Scholar
• Murray PB, Lax I, Reshetnyak A, Ligon GF, Lillquist JS, Natoli EJ, Jr, et al. 2015. Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK. Sci Signal. 20:ra6.
   Web of Science ®Google Scholar
• Nidhin M, Indumathy R, Sreeram KJ, Nair BU. 2008. Synthesis of iron oxide nanoparticles of narrow size distribution on polysaccharide templates. Bull Mater Sci. 31:93–96.
   Web of Science ®Google Scholar
• Ono K, Ishihara M, Ishikawa K, Ozeki Y, Deguchi H, Sato M, et al. 2002. Periodate-treated, non-anticoagulant heparin carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung. Br J Cancer. 86:1803–1812.
   PubMed Web of Science ®Google Scholar
• Park K, Kim K, Kwon IC, Kim SK, Lee S, Lee DY, Byun Y. 2004. Preparation and characterization of self-assembled nanoparticles of heparin-deoxycholic acid conjugates. Langmuir. 20:11726–11731.
   PubMed Web of Science ®Google Scholar
• Pinon-Segundo E, Ganem-Quintanar A, Alonso-Perez V, Quintanar-Guerrero D. 2005. Pharmaceutical nanotechnology preparation and characterization of triclosan nanoparticles for periodontal treatment. Int J Pharm. 294:217–232.
   PubMed Web of Science ®Google Scholar
• Polakovic M, Gorner T, Gref R, Dellacherie E. 1999. Lidocaine loaded biodegradable nanospheres. II. Modelling of drug release. J Control Release. 60:169–177.
   PubMed Web of Science ®Google Scholar
• Shakeel F, Alanazi FK, Raish M, Haq N, Radwan AA, Alsarra IA. 2015. Pharmacokinetic and in vitro cytotoxic evaluation of cholesterol-rich nanoemulsion of cholesteryl-succinyl-5-fluorouracil. J Mol Liq. 211:164–168.
   Web of Science ®Google Scholar
• Shakeel F, Haq N, Aldhfyan A, Alanazi FK, Alsarra IA. 2014. Double w/o/w nanoemulsion of 5-fluorouracil for self-nanoemulsifying drug delivery system. J Mol Liq. 200:183–190.
   Web of Science ®Google Scholar
• Shakeel F, Haq N, Aldhfyan A, Alanazi FK, Alsarra IA. 2015. Chemoprevention of skin cancer using low HLB surfactant nanoemulsion of 5-fluorouracil: a preliminary study. Drug Deliv. 22:573–580.
   PubMed Web of Science ®Google Scholar
• Shi L, Farber JN, Michaels KC, Dickey A, Thompson KC, Shelukar SD, et al. 2003. Characterization of crystalline drug nanoparticles using atomic force microscopy and complementary techniques. Pharm Res. 20:479–484.
   PubMed Web of Science ®Google Scholar
• Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK. 2010. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J. 277:3904–3923.
   PubMed Web of Science ®Google Scholar
• Tomuta AM, Ramis X, Ferrandoc F, Serra A. 2012. The use of dihydrazides as latent curing agents in diglycidyl ether of bisphenol a coatings. Progress Org Coat. 74:59–66.
   Web of Science ®Google Scholar
• Xie J, Hwa Wang C. 2004. Paclitaxel-loaded biodegradable nanoparticles developed by direct dialysis and electrodydrodynamic atomization methods. AIChE Annual Meeting, Texas; 7–12.
   Google Scholar
• Yadav AK, Agarwal A, Jain S, Mishra AK, Bid H, Rai G, Agrawal H, Agrawal GP. 2010. Chondroitin sulphate decorated nanoparticulate carriers of 5-fluorouracil: development and in vitro characterization. J Biomed Nanotechnol. 6:1–11.
   PubMed Web of Science ®Google Scholar
• Yadav AK, Mishra P, Jain S, Mishra P, Mishra AK, Agrawal GP. 2008. Preparation and characterization of HA–PEG–PCL intelligent core–corona nanoparticles for delivery of doxorubicin. J Drug Target. 6:464–478.
   Web of Science ®Google Scholar
• Yadav AK, Mishra P, Mishra AK, Mishra P, Jain S, Agrawal GP. 2007. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Nanomedicine. 3:246–257.
   PubMed Web of Science ®Google Scholar
• Yoshitomi Y, Nakanishi H, Kusano Y, Munesue S, Oguri K, Tatematsu M. 2004. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Lett. 207:165–174.
   PubMed Web of Science ®Google Scholar